Physician profile
Nirav Sheth
NPI 1134137144
$9,109.86
in general payments reported to CMS, 2019-2025
51 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,556 · 2021: $1,409 · 2022: $1,166 · 2023: $1,065 · 2024: $1,144 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.43 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $939.94 | 2019-2022 | |
| Amgen INC. | $817.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $651.22 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $646.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $524.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $518.97 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Allergan, INC. | $510.72 | 2019-2020 | |
| Astellas Pharma US INC | $426.64 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $390.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $378.74 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $349.11 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Amarin Pharma, INC. | $347.73 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.34 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $301.83 | 2019-2023 | |
| Mylan Specialty L.P. | $252.02 | 2019-2024 | Yupelri |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.